A Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

About this Study

The purpose of this study is to research the effects, good or bad of Ateozolizumab on ovarian, fallopian tube, or primary peritoneal cancer.

Sponsor Protocol ID:GOG 3015/YO39523
IRB Number:2017-0109
Closed for Enrollment
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Signed Informed Consent Form. 
  • Age > 18 years. 
  • Able to comply with the study protocol, in the investigator’s judgment. 
  • Life expectancy > 12 weeks. 
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria
  • Are pregnant, lactating, or intend to become pregnant during the study. 
  • Have a positive test result for HIV. 
  • Have active tuberculosis. 
  • Have severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia. 
  • Have received therapeutic oral or IV antibiotic medication within 2 weeks prior to initiation of study treatment.
  • Have significant cardiovascular disease. 
  • Have any approved or investigational anti-cancer therapy, including chemotherapy or hormonal therapy. 
  • History of leptomeningeal disease. 
  • Have clinical signs of gastrointestinal obstruction that require routine parenteral hydration, parenteral nutrition, or tube feeding.  
  • Have evidence of abdominal free air not explained by paracentesis or recent surgical procedure. 
  • Have serious, non-healing wound, active ulcer, or untreated bone fracture. 

Categories Click category to view its trials.
Cancer
Women's Health
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Wiser Hospital for Women and Infants - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Ridgway, Mildred, M.D.
How to participate in our Clinical Trials